Castle Biosciences (CSTL) Accumulated Expenses (2018 - 2026)

Castle Biosciences has reported Accumulated Expenses for 9 years, with the latest figure at $26.9 million in Q2 2026.

• Quarterly Accumulated Expenses rose 7.69% year-over-year to $26.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $26.9 million (up 7.69% YoY) and the FY2025 annual result came in at $38.3 million, up 17.61% from the prior year.
• Accumulated Expenses rose to $26.9 million in Q2 2026 per CSTL's latest filing, from $19.1 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $38.3 million in Q4 2025 and troughed at $8.6 million in Q1 2022.
• A 5-year average of $22.4 million and a median of $21.8 million in 2023 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2026: Accumulated Expenses surged 73.0% in 2022, then grew 7.02% in 2026.
• Over 5 years, Accumulated Expenses stood at $24.4 million in 2022, then climbed by 18.83% to $28.9 million in 2023, then climbed by 12.47% to $32.6 million in 2024, then climbed by 17.61% to $38.3 million in 2025, then fell by 29.76% to $26.9 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $26.9 million, $19.1 million, and $38.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.